Teva Parenteral Medicines, Inc., Baxter Healthcare Corp., and McKesson Corp. have been ordered by a jury to pay at least $20.1 million for packaging and selling an anesthetic in a way that proved harmful to patients. The jury concluded that the companies wrongfully sold Propofol in vials large enough to be used on multiple patients. Consequently, three colonoscopy patients contracted Hepatitis C. The plaintiffs sought $25 million in actual damages over the incurable liver disease. Punitive damages have yet to be decided.
Teva faces almost 300 lawsuits stemming from a Hepatitis C outbreak three years ago. The company has argued that the infections were caused by “improperly sanitized medical equipment, not reused Porpofol containers.”
About McAleer Law: